Evidence map›Paper›PMID 19571563›Full record

ReviewInternational archives of allergy and immunology2009

Common variable immunodeficiency: etiological and treatment issues.

Sean Deane, Carlo Selmi, Stanley M Naguwa, Suzanne S Teuber, M Eric Gershwin

Erratum issued Registry-linked trialAbstract readReview
In one paragraph

Review in International archives of allergy and immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03339778 (An Investigator Driven Observational Study to Determine the Benefit of Octagam 5% for Treatment of Patients Diagnosed With Primary Immunodeficiency Disorders), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03339778 completednot on this mapstarted 2015, after this paper: background citation

An Investigator Driven Observational Study to Determine the Benefit of Octagam 5% for Treatment of Patients Diagnosed With Primary Immunodeficiency Disorders (PID) on Intravenous Immunoglobulin (IVIG) Therapy That Experience Adverse Events (AEs) on Any 10% IVIG Preparation

TypeobservationalSponsorIMMUNOe Research CentersRan2015 to 2017Enrolled15ConditionsPrimary Immunodeficiency
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2022
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

  • Erratum issued
    Dosage error in article text
5 · Who and what money

Authors and funding

5 authors.

Sean DeaneDivision of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, Davis, California 95616, USA.
Carlo Selmi
Stanley M Naguwa
Suzanne S Teuber
M Eric Gershwin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the great advances in clinical medicine was the recognition of the pleomorphism of the immune response and the multiple afferent and efferent limbs of antigen processing and responsiveness. A significant contribution to this understanding was derived from studies of human immunodeficiency states, including both inherited and acquired syndromes. Amongst these syndromes, one of the most common, and least understood, is common variable immune deficiency (CVID). CVID is a syndrome that leads to a reduction in serum immunoglobulins and complications including recurrent infections. Management includes immunoglobulin replacement therapy; however, patients with CVID are at risk for complications of exogenous immunoglobulin administration as well as CVID-associated diseases such as autoimmune processes and malignancies. To assess the current state of knowledge in the field, we performed a literature review of a total of 753 publications covering the period of 1968 until 2008. From this list, 189 publications were selected for discussion. In this review, we demonstrate that while the molecular basis of CVID in many cases remains incompletely understood, significant strides have been made and it is now clear that there is involvement of several pathways of immune activation, with contributions from both T and B cells. Furthermore, despite the current gaps in our knowledge of the molecular pathogenesis of the syndrome, there have been dramatic advances in management that have led to improved survival and significantly reduced morbidity in affected patients.

Indexed as

AnimalsAnti-Bacterial AgentsAutoimmune DiseasesB-LymphocytesCommon Variable ImmunodeficiencyHumansImmunoglobulins, IntravenousInfectionsLymphocyte ActivationMonitoring, PhysiologicNeoplasmsT-LymphocytesAnti-Bacterial AgentsImmunoglobulins, Intravenous

Identifiers

PMID19571563
PMCPMC2814150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.